Neurocognitive and behavioural performance of healthy volunteers receiving an increasing analgesic-range infusion of ketamine.

The open-label, non-controlled trial design somewhat precludes the ability to adequately account for random treatment effects. Notwithstanding, these results suggest that analgesic doses of ketamine produce acute, selective, dose-dependent deficits in higher-order neurocognitive and behavioural domains.